Skip to main content
SpringerLink
Log in

The clinical significance of axillary sentinel lymph node biopsy in different clinical stages breast cancer patients after neoadjuvant chemotherapy

  • Published:
The Chinese-German Journal of Clinical Oncology

Abstract

Objective

We aimed to study the success and false negative rate of sentinel lymph node biopsy (SLNB) in different clinical stages breast cancer patients being carried out with neoadjuvant chemotherapy (NAC), and the clinical significance of SLNB, we conducting this trial.

Methods

One hunderd and thirty-seven cases were enrolled in this clinical research from March 2003 to March 2007. All of the patients’ sentinel lymph nodes were detected with 99mTc-Dx and methylene blue. There were 61 patients with stage T1–2N0M0 carried SLNB without NAC (group A), 76 cases were carried out NAC 3–4 cycles before SLNB, including 39 T2–4N0–1M0 cases (group B) and 27 T2–4N2–3M0 cases (group C). The success and false negative rate of SLNB were analysed with chi-square test.

Results

In group A, the successful and false negative rate of SLNB were 92.31% (36/39), 8.57% (3/35), and in group B and C were 92.31% (36/39), 8.57% (3/35) and 74.07 % (20/27), 18.52 % (5/27), respectively. The successful rate of group C decreased and false negative rate increased significantly compared with group A and B (P < 0.05), but group A and B had no significant difference (P > 0.05).

Conclusion

The SLNB can accurately predict lymph node status of axillary lymph node in N0–1 stage patients with NAC, but in N2–3 stage patients the success rate decreased and false rate increased negative significantly.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Liu W, Zhang XH, Zhang ZG, et al. Effect of neoadjuvant CAF regimen on the expression of BCSG1 in breast cancer. Chinese-German J Clin Oncol, 2006, 5: 272–274.

    Article  CAS  Google Scholar 

  2. Kim T, Giuliano AE, Lyman GH. Lymphatic mapping and sentinel lymph node biopsy in early-stage breast carcinoma: a metaanalysis. Cancer, 2006, 106: 4–16.

    Article  PubMed  Google Scholar 

  3. Schwartz GF, Giuliano AE, Veronesi U. Consensus Conference Committee. Proceedings of the Consensus Conference on the role of sentinel lymph node biopsy in carcinoma of the breast April 19–22, 2001, Philadelphia, Pennsylvania. Hum Pathol, 2002, 33: 579–589.

    Google Scholar 

  4. Seok JW, Choi YS, Chong S, et al. Sentinel lymph node identification with radiopharmaceuticals in patients with breast cancer: a comparison of 99mTc-tin colloid and 99mTc-phytate efficiency. Breast Cancer Res Treat, 2010, 122: 453–457.

    Article  CAS  PubMed  Google Scholar 

  5. Cody HS, Fey J, Akhurst T, et al. Complementarity of blue dye and isotope in sentinel nodel ocalization for breast cancer: univariate and multivariate analysis of 966 procedures. Ann Surg Oncol, 2001, 8: 13–19.

    Article  PubMed  Google Scholar 

  6. Borgstein PJ, Meijer S, Pijpers RJ, et al. Functional lymphatic anatomy for sentinel node biopsy in breast cancer: echoes from the past and the periareolar blue method. Ann Surg, 2000, 232: 81–89.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  7. Kern KA. Breast lymphatic mapping using subareolar injections of blue dye and radiocolloid: illustrated technique. J Am Coll Surg, 2001, 192: 545–550.

    Article  CAS  PubMed  Google Scholar 

  8. Bear HD. Neoadjuvant chemotherapy for operable breast cancer: individualizing locoregional and systemic therapy. Surg Oncol Clin N Am, 2010, 19: 607–626.

    Article  PubMed  Google Scholar 

  9. Kang SH, Kang JH, Choi EA, et al. Sentinel lymph node biopsy after neoadjuvant chemotherapy. Breast Cancer, 2004, 11: 233–241.

    Article  PubMed  Google Scholar 

  10. Mamounas EP, Brown A, Anderson S, et al. Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol, 2005, 23: 2694–2702.

    Article  PubMed  Google Scholar 

  11. Xing Y, Foy M, Cox DD, et al. Meta-analysis of sentinel lymph node biopsy after preoperative chemotherapy in patients with breast cancer. Br J Surg, 2006, 93: 539–546.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Breast Cancer, Hubei Cancer Hospital, Wuhan, 430079, China

    Juan Xu, Xinhong Wu, Yaojun Feng, Feng Yuan & Wei Fan

Authors
  1. Juan Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xinhong Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yaojun Feng
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Feng Yuan
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Wei Fan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Xinhong Wu.

Additional information

Supported by a grant from the Medical Foundation of Hebei Provincial Health Bureau (No. NX200615).

Rights and permissions

Reprints and permissions

About this article

Cite this article

Xu, J., Wu, X., Feng, Y. et al. The clinical significance of axillary sentinel lymph node biopsy in different clinical stages breast cancer patients after neoadjuvant chemotherapy. Chin. -Ger. J. Clin. Oncol. 12, 521–523 (2013). https://doi.org/10.1007/s10330-013-1251-6

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10330-013-1251-6

Key words

Search

Navigation